The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer

ConclusionThe budget impact of adding rucaparib to the formulary for a health plan adds negligible PMPM costs of< US$0.001 in all tested settings and scenarios due to the small population eligible for therapy.

http://link.springer.com/10.1007/s40273-020-00970-y

Source: PharmacoEconomics - November 4, 2020 Category: Health Management Source Type: research